Niagen Bioscience, Inc.

Listed Company

NAGECIK 0001386570NasdaqLarge AcceleratedMedicinal Chemicals & Botanical ProductsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$129.42M

Net Income

$17.38M

Total Assets

$106.41M

Equity

$76.53M

Shares Out

79.64M

Op. Cash Flow

$13.50M

NAGE$3.28−68.39% · past yearDBEQ Basic

Daily closing prices

Business

Niagen Bioscience, Inc. is a global bioscience company dedicated to promoting healthy aging through the development and commercialization of NAD+ precursors, primarily nicotinamide riboside (NR). The company offers finished dietary supplements under the Tru Niagen® brand, proprietary ingredient technologies in food-grade and pharmaceutical-grade forms, and analytical reference standards and services. Products are distributed through direct-to-consumer e-commerce platforms, third-party online marketplaces, strategic distribution partners internationally, and to manufacturers and 503B outsourcing facilities.

Summary from 10-K filed 2026-03-04

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Sales, net	129	100	84	72	67
Cost of sales	46	38	33	29	26
Gross profit	83	62	51	43	41
Sales and marketing	36	29	26	28	28
Research and development	6	6	5	5	4
General and administrative	27	18	25	28	36
Gain on settlement of royalty obligation	−2	0	—	—	—
Total operating expenses, net	67	54	56	61	69
Operating income	16	8	−6	−19	−27
Investment Income, Interest	2	1	—	—	—
IRS ERTC disallowance	−214,000	0	—	—	—
Total nonoperating income, net	2	1	661,000	—	—
Income before provision for income taxes	18	9	−5	—	—
Provision for income taxes	810,000	305,000	0	—	—
Net income	17	9	−5	−17	−27
Basic (in dollars per share)	0.22	0.11	−0.07	−0.24	−0.4
Diluted (in dollars per share)	0.2	0.11	−0.07	−0.24	−0.4
Basic (in shares)	79	76	75	70	67
Diluted (in shares)	85	78	75	70	67

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-09-30	FY 2022 2022-12-31
Cash and cash equivalents, including restricted cash of $152 for both periods presented	65	45	27	—	20
Trade receivables, net of allowances of $147 and $95, respectively	10	8	—	—	8
Inventories	20	9	—	—	—
Assets held for sale	541,000	0	—	—	—
Prepaid expenses and other assets	1	2	2	—	3
Total current assets	97	64	50	—	47
Leasehold improvements and equipment, net	1	2	2	—	3
Intangible assets, net	6	359,000	510,000	—	671,000
Right-of-use assets	2	2	2	1	4
Other long-term assets	425,000	368,000	383,000	—	497,000
Total assets	106	68	55	—	54
Accounts payable	11	9	10	—	10
Accrued expenses	8	8	9	—	7
Current maturities of operating lease obligations	1	982,000	691,000	—	680,000
Current maturities of finance lease obligations	0	12,000	11,000	—	16,000
Customer deposits	399,000	611,000	195,000	—	157,000
Total current liabilities	20	18	21	—	18
Deferred revenue	3	3	3	—	4
Operating lease obligations, less current maturities	2	2	3	—	4
Deferred consideration liability	5	0	—	—	—
Total liabilities	30	22	27	—	25
Commitments and Contingencies (Notes 9 and 15)	—	—	—	—	—
Common stock, $0.001 par value; authorized 150,000 shares; 79,714 shares and 77,330 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively.	79,000	77,000	75,000	—	74,000
Additional paid-in capital	241	228	219	—	214
Accumulated deficit	−165	−182	−190	—	−185
Cumulative translation adjustments	−9,000	−4,000	−4,000	—	−3,000
Total stockholders' equity	77	46	28	—	29
Total liabilities and stockholders' equity	106	68	55	—	54

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation of leasehold improvements and equipment	612,000	663,000	870,000	869,000	890,000
Amortization of intangibles	173,000	151,000	158,000	186,000	225,000
Noncash lease expense	665,000	670,000	677,000	—	—
Share-based compensation expense	6	4	5	6	6
Loss (gain) on sale or disposal of leasehold improvements and equipment	4,000	−19,000	−5,000	7,000	0
Allowance for (Recovery of) credit losses	−1	−1	964,000	63,000	46,000
Reversal of previously accrued royalties and license maintenance fees	0	−4	0	—	—
Interest accretion on deferred consideration	38,000	0	—	—	—
Non-cash financing costs	59,000	80,000	75,000	67,000	108,000
Trade receivables	−756,000	−1	2	−3	−3
Inventories	−12	5	152,000	−1	−2
Implementation costs for cloud computing arrangement	−66,000	−83,000	−60,000	−304,000	−278,000
Prepaid expenses and other assets	1	−45,000	631,000	−872,000	−810,000
Accounts payable	2	−1	553,000	−744,000	978,000
Accrued expenses	2	1	2	856,000	348,000
Deferred revenue	95,000	−732,000	−644,000	−391,000	−95,000
Customer deposits and other	−217,000	416,000	38,000	−5,000	−116,000
Operating lease liabilities	−949,000	−615,000	−519,000	−463,000	−541,000
Net cash provided by operating activities	14	12	7	−15	−24
Purchases of leasehold improvements and equipment	−292,000	−163,000	−148,000	−334,000	−409,000
Proceeds from the sale of leasehold improvements and equipment, net	0	20,000	5,000	0	—
Net cash used in investing activities	−292,000	−143,000	−143,000	−334,000	−409,000
Proceeds from exercise of stock options	7	5	0	0	9
Repurchase of common stock	−251,000	0	—	—	—
Payment of debt issuance costs	−67,000	−52,000	−75,000	−77,000	−110,000
Principal payments on finance leases	−12,000	−11,000	−15,000	−16,000	−31,000
Net cash provided by financing activities	7	5	−90,000	8	36
Net increase in cash and cash equivalents	20	17	7	−8	12
Cash payments for interest on finance leases	1,000	1,000	2,000	1,000	1,000
Cash payments for principal on operating lease liabilities	873,000	600,000	610,000	507,000	541,000
Right-of-use assets and operating lease obligations incurred for entering into lease amendment	1	0	446,000	0	—
Acquisition of patent intangible asset and deferred consideration liability	5	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Niagen Bioscience, Inc.'s CIK number?

Niagen Bioscience, Inc.'s SEC CIK number is 0001386570 (1386570). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Niagen Bioscience, Inc.'s SEC filings?

All of Niagen Bioscience, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Niagen Bioscience, Inc. last report earnings?

Niagen Bioscience, Inc. (NAGE) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001386570-26-000031). This is Niagen Bioscience, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Niagen Bioscience, Inc.'s most recent earnings 8-K?

Niagen Bioscience, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001386570-26-000031. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Niagen Bioscience, Inc.'s latest earnings 8-K →
Look up any company's CIK number →